Business Context and Reporting Period
Apogee Therapeutics, Inc. (APGE) filed a Form 8-K on May 26, 2026, reporting the entry into a Material Definitive Agreement. The Company is a biopharmaceutical firm developing zumilokibart (APG777), an anti-IL-13 antibody for atopic dermatitis.
Key Financial Metrics and Transaction Details
The Company entered into a Revenue Participation Right Purchase and Sale Agreement with Annapurna Aggregator L.P. (BXLS), an affiliate of Blackstone Life Sciences.
- Upfront Funding: $100.0 million received immediately (Tranche 1).
- Contingent Funding:
- Tranche 2: $100.0 million upon full enrollment of Phase 3 trials.
- Tranche 3: $200.0 million upon positive Phase 3 data readouts.
- Tranche 4: $250.0 million to $400.0 million upon FDA approval by December 31, 2030.
- Total Potential Funding: Up to $800.0 million in equity-like revenue share financing.
- Revenue Share Terms: BXLS receives tiered percentages of annual worldwide net product sales of zumilokibart.
- Tier 1 (Up to $5B sales): Base rate of 0.9375% (doubling with Tranche 2 and 3) plus a Tranche 4 rate of 2.50% (if triggered), totaling up to 3.4375%.
- Tier 2 ($5B - $8B sales): Base rate of 0.25%.
- Term: Payments commence on first commercial sale and end on the 15th anniversary of marketing approval.
- Security: BXLS holds a backup security interest in the revenue rights and intellectual property related to zumilokibart.
- Debt Option: Parties agreed to negotiate a debt financing of up to $500.0 million.
Material Changes and Guidance
As a direct result of this transaction, the Company is removing its previously issued cash runway end date guidance. The filing does not provide specific historical revenue, profit, or cash flow figures for the current or prior periods, as this is a current report focused on a specific agreement.
Outlook, Risks, and Contingencies
- Change of Control: The agreement includes provisions for a specified payment to BXLS in the event of a change of control, which can be credited against future revenue shares. Alternatively, the Company has a "Buy-Back Option" to pay specified amounts to reduce future revenue share percentages.
- Tranche 4 Cap: Tranche 4-related revenue share payments are capped at $1.0 billion in aggregate.
- Regulatory Risk: Tranche 4 funding is contingent on FDA approval by December 31, 2030.
- Operational Risk: Tranche 2 and 3 funding depend on clinical trial enrollment and positive data readouts.
Investor Verification Checklist
- Verify the exact terms of the "Buy-Back Option" and the specific amounts required to exercise it.
- Confirm the timeline for the Phase 3 clinical trials (APG777-301 and APG777-302) to assess the likelihood of Tranche 2 and 3 funding.
- Review the full text of the Revenue Share Agreement (to be filed as an exhibit to the Q2 2026 10-Q) for detailed definitions of "Net Sales" and tiered calculation mechanics.
- Monitor the status of the potential $500.0 million debt financing negotiation.
- Assess the impact of the backup security interest on the Company's ability to license or sell the zumilokibart asset independently.